[Phase II study of 5'-DFUR (Furtulon) capsule for bladder cancer]

Y Kubota; T Miura; T Shuin; Y Kinoshita; M Hosaka; I Kondo; M Moriyama; S Fukushima; H Fukuoka; K Miyai

[Phase II study of 5'-DFUR (Furtulon) capsule for bladder cancer]

Gan To Kagaku Ryoho. 1991 Oct;18(13):2301-6.

[Article in Japanese]

Authors

Y Kubota¹, T Miura, T Shuin, Y Kinoshita, M Hosaka, I Kondo, M Moriyama, S Fukushima, H Fukuoka, K Miyai, et al.

Affiliation

¹ Dept. of Urology, Yokohama City University School of Medicine.

PMID: 1834023

Abstract

A cooperative phase II study of 5'-DFUR at a daily dose of 800 to 1,200 mg was performed on 18 patients with bladder cancer. The therapeutic responses were evaluated by Koyama-Saito's criteria in 13 out of 18 patients, and 3 PR, 1 MR, 6 NC and 3 PD were obtained. Adverse reactions were observed in three out of 15 cases (20.0%). These side effects were reversible gastrointestinal symptoms such as nausea-vomiting, anorexia and diarrhea. The results suggest that 5'-DFUR is a useful drug for bladder cancer treatment.

Publication types

English Abstract

MeSH terms

Adenocarcinoma / drug therapy
Adult
Aged
Aged, 80 and over
Anorexia / chemically induced
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Carcinoma, Squamous Cell / drug therapy
Carcinoma, Transitional Cell / drug therapy*
Diarrhea / chemically induced
Drug Administration Schedule
Drug Evaluation
Female
Floxuridine / administration & dosage
Floxuridine / adverse effects
Floxuridine / therapeutic use*
Humans
Male
Middle Aged
Nausea / chemically induced
Urinary Bladder Neoplasms / drug therapy*

Substances

Antineoplastic Agents
Floxuridine
doxifluridine